Skip to content

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy with Atrasentan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-054-13
Enrollment
93
Registered
2013-12-26
Start date
2014-02-03
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Atrasentan 0.75mg tablet per day Oral

Sponsors

AbbVie Inc o tambien conocido como AbbVie,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Subject is 18 – 85 years of age. 2. Subject has voluntarily signed and dated an Informed Consent Form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed. 3. Subject has type 2 diabetes and has been treated with at least one anti-hyperglycemic medication and ACEi/or ARB (RAS inhibitor) for at least 3 months prior to the Screening Period. Subject cannot have type 1 diabetes as defined by onset before age 35 requiring chronic insulin therapy within 12 months of diagnosis of type 1 diabetes. 4. HbA1c ≤ 12%. The rest of the information is included in the protocol.

Exclusion criteria

Exclusion criteria: 1. Subject has a history of moderate or severe peripheral edema, pulmonary edema or facial edema unrelated to trauma or a history of myxedema in the prior 6 months to Screening. 2. Subject has a history of pulmonary hypertension requiring oxygen therapy, and/or endothelin receptor antagonist or phosphodiesterase therapy or any lung diseases requiring oxygen therapy (e.g., chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis). 3. Subject has a documented diagnosis of heart failure, previous hospitalization for heart failure or current or constellation of symptoms (dyspnea on exertion, pedal edema, orthopnea, paroxysmal nocturnal dyspnea) felt to be compatible with heart failure, that was not explained by other causes, and for which there was a change in medication or other management directed at heart failure. 4. Subject has known non-diabetic kidney disease (other than kidney stones). 5. Subject has a history of symptomatic hypotension within the last 6 months. 6. Subject has a body mass index (BMI) > 45. The rest of the information is included in the protocol.

Countries

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Korea South, Malasya, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States

Contacts

Public ContactGiselle Vasquez

INVENTIV HEALTH CLINICAL PERU S.A

Giselle.Vasquezgavidia@inventivhealth.com994002113

Outcome results

None listed

Source: REPEC (via WHO ICTRP)